Lafazanos Yannis, David Robin, Asado Nahren, Gonzalez Miguel, Ehrenpreis Eli D
Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL.
Department of Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.
ACG Case Rep J. 2025 Jul 21;12(7):e01756. doi: 10.14309/crj.0000000000001756. eCollection 2025 Jul.
Pembrolizumab is a programmed cell death-1 (PD-1) inhibitor frequently used as primary immunotherapy in many cancers, including melanoma, lung, renal cell, cervical, urothelial, and gastric cancers. Given its immune-checkpoint inhibition and upregulation of the immune response, pembrolizumab has been associated with many immune system-related adverse effects including stomatitis, conjunctivitis, pneumonitis, myositis, and even type 1 diabetes mellitus. Colitis is the most frequent gastrointestinal adverse reaction, with upper gastrointestinal reactions like esophagitis, gastritis, and duodenitis being rare. In this report, we present a case of pembrolizumab-induced enteropathy that endoscopically and histologically mimicked celiac disease.
帕博利珠单抗是一种程序性细胞死亡蛋白1（PD-1）抑制剂，常用于包括黑色素瘤、肺癌、肾细胞癌、宫颈癌、尿路上皮癌和胃癌在内的多种癌症的一线免疫治疗。鉴于其免疫检查点抑制作用和免疫反应上调，帕博利珠单抗与许多免疫系统相关不良反应有关，包括口腔炎、结膜炎、肺炎、肌炎，甚至1型糖尿病。结肠炎是最常见的胃肠道不良反应，而食管炎、胃炎和十二指肠肠炎等上消化道反应则较为罕见。在本报告中，我们介绍了一例帕博利珠单抗诱发的肠病病例，该病例在内镜检查和组织学上酷似乳糜泻。
